COMMUNIQUÉS West-GlobeNewswire

Spectral Medical Announces Third Quarter Results and Provides Corporate Update
08/11/2024
Tigris Trial Enrollment at 135 Patients Strengthened Balance Sheet with Expected Funds to Complete Tigris Trial Enrollment TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) ( [...]
Humacyte Third Quarter 2024 Financial Results and Business Update
08/11/2024
- FDA review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma is ongoing - - Results from the V007 Phase 3 clinical trial of the ATEV in arteriovenous (AV) access for hemodialysis [...]
Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter
07/11/2024
World’s First Enhanced Small Particle (ESP™) Detection Sorter Enables Effective Content Isolation; Opens Door to Scientific Discoveries FREMONT, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq [...]
Tilray Medical annonce les résultats positifs d’une étude sur l’extrait de cannabis oral dans le traitement des vomissements induits par la chimiothérapie
07/11/2024
SYDNEY, Australie, 07 nov. 2024 (GLOBE NEWSWIRE) -- Tilray Medical, une division de Tilray Brands, Inc., ci-après « Tilray Brands » (NASDAQ : TLRY et TSX : TLRY) et leader mondial du cannabis thérapeutique, qui permet [...]
Teladoc Health Announces Employee Inducement Awards Under NYSE Rule 303A.08
07/11/2024
PURCHASE, NY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, today announced that it issued inducement awards to two new employees. Effective November [...]
Notice of General Meeting
07/11/2024
November 7, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of [...]
BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates
07/11/2024
Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity Completed $238.3 million initial public offering and concurrent private placement, cash and cash equivalents sufficient to fund [...]
Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update
07/11/2024
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate [...]
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
07/11/2024
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies [...]
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
07/11/2024
Less frequent IV dosing with nemvaleukin in patients with select advanced solid tumors, including ovarian cancer and mucosal melanoma, showed tumor site-specific pharmacodynamic activity and immune activation [...]
AMN Healthcare Announces Third Quarter 2024 Results
07/11/2024
Quarterly revenue of $688 million ; GAAP EPS of $0.18 and adjusted EPS of $0.61 DALLAS, Nov. 07, 2024 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for [...]
Dyne Therapeutics to Present at Upcoming Investor Conferences
07/11/2024
WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with [...]
GENFIT Reports Third Quarter 2024 Financial Information
07/11/2024
Cash and cash equivalents totaled €96.0 million as of September 30, 2024 €59.7 million in revenues for the nine months ended September 30, 2024, including the €48.7 million milestone invoiced in June 2024 (received in [...]
GENFIT : Information financière du troisième trimestre 2024
07/11/2024
Trésorerie et équivalents de trésorerie s’élevant à 96,0 millions d’euros au 30 septembre 2024 59,7 millions d’euros de revenus des neuf premiers mois de 2024, dont 48,7 millions d'euros de paiement d'étape facturés en [...]
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
07/11/2024
- Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager) continues to advance. Potential Phase 1b initiation in 2025. - - Phase 1 study of CX-2051 (EpCAM PROBODY® ADC) in advanced colorectal cancer (CRC [...]
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
07/11/2024
Pre-planned Phase 3 Reliance II interim analysis, anticipated by YE 2024, could represent an important de-risking event for REL-1017 and the Company Phase 1 study for REL-P11 for metabolic disease expected to begin by [...]
Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results
07/11/2024
GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-year Strong cumulative prescriber growth, 45% year-over-year increase 52% year-over-year prescription [...]
Lifeward Announces Appointment of Robert J. Marshall to Its Board of Directors
07/11/2024
Financial executive brings over 30 years of experience and leadership in financial management and strategy MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“ [...]
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
07/11/2024
Prioritize and focus resources on LNCB74 (B7-H4 ADC) with a planned IND submission by year-end Cash of approximately $75 million expected to fund operations into second half of 2026 BELTSVILLE, Md., Nov. 07, 2024 (GLOBE [...]

Pages